Le Lézard
Classified in: Health, Business
Subject: CXP

EVIO Labs Massachusetts Announces Relocation to Framingham


BEND, Ore., Sept. 18, 2018 /PRNewswire/ -- EVIO Inc. ("EVIO" or the "Company"), (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, announced that its Massachusetts lab has engaged in a Community Host agreement with the City of Framingham to proceed with licensing as an independent testing laboratory under the Commission's recently adopted adult use regulations.  This is on the heels of the announcement that the lab had received ISO 17025 accreditation and is awaiting licensing approval from the Cannabis Control Commission.

EVIO Logo (PRNewsfoto/EVIO, Inc.)

The lab will move to a 5,000 square foot facility that is centrally located to serve marijuana establishments statewide.  Massachusetts law requires that all recreational marijuana products have been tested by a Commission-licensed independent laboratory for contaminants and potency levels. The Commonwealth's adult-use cannabis market is expected to exceed $1 billion by 2021.

"There are approximately 80 marijuana establishments awaiting licensing, all of which will require testing.  We are scaling up operations considerably to meet the coming adult-use demand for cannabis by year-end.   We expect to be one of just three or four operating labs and are actively hiring for all positions in the lab," said Lori Glauser, COO of EVIO.

About EVIO Inc.
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company's EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply.  The Company's EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system. For more information, visit www.eviolabs.com.

Safe Harbor Statement
Any statements in this press release that are not statements of historical fact maybe considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or www.eviolabs.com.

CONTACT INFORMATION
Cheryl Kramp
Director of Marketing
EVIO Inc.
888.544.EVIO
[email protected]

 

SOURCE EVIO Inc.


These press releases may also interest you

at 18:30
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four...

at 18:16
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 17:56
The Canadian Cancer Society commends the increases in taxes on tobacco and e-cigarettes in today's federal budget.  The budget increases tobacco taxes by $4.00 per carton of 200 cigarettes effective at midnight, and increases e-cigarette taxes by 12%...

at 17:45
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to...

at 17:31
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...

at 17:26
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIREŽ (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...



News published on and distributed by: